Tracking postpartum depression symptoms after starting zuranolone
Official title: A Longitudinal Online Survey of Patient-Reported Changes in Postpartum Depression Symptoms Following Zuranolone Use
Run by Biogen · NCT07398469 · Data updated 2026-11-12
This study will see how postpartum depression symptoms change in people who start taking zuranolone within a year after giving birth.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 300 (estimated) |
| Sponsor | Biogen Industry-sponsored |
| Locations | 1 site (Cambridge, Massachusetts) |
| Status | Recruiting |
| Started | December 22, 2025 |
| Main results expected | March 29, 2027 |
| Study ends | March 29, 2027 |
| Registry record updated | September 8, 2026 |
| Trial ID | NCT07398469 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people in the U.S. within 12 months after pregnancy who have a confirmed diagnosis of postpartum depression and a new prescription for zuranolone, can complete surveys in English, and have not recently used zuranolone or brexanolone.
✕Probably not a fit
People with a history of bipolar disorder, those who already filled or started zuranolone or brexanolone in the past 12 months, non-English speakers, or those more than 12 months postpartum are unlikely to qualify or benefit from this observational data.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will follow people in the United States who have a new prescription for zuranolone to track symptom changes over 90 days. Participants are identified via Accredo Specialty Pharmacy and complete the Edinburgh Postnatal Depression Scale (EPDS) at baseline, Day 15 (primary), Day 45, and Day 90, along with surveys on breastfeeding and medication use. The study does not change participants' medical care and relies on self-reported outcomes and treatment patterns. People with recent prior fills of zuranolone or brexanolone, a history of bipolar disorder, or an inability to complete English questionnaires are excluded.
Why it matters
Potential benefit: If successful, the study could give clinicians and patients clearer, real-world information on how quickly and how long zuranolone may help postpartum depression symptoms and how it is used during the first 90 days.
How similar studies have gone: Previous clinical trials of zuranolone and related neuroactive steroids have shown rapid symptom improvements in some people with PPD, but long-term and real-world data like this are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Key Inclusion Criteria: * Participants with a prescription for zuranolone via Accredo Specialty Pharmacy. * Recent pregnancy in the last 12 months. * Confirmed diagnosis of PPD. * Able to complete the questionnaires by themselves in English. Key Exclusion Criteria: * Prior fill of zuranolone or brexanolone in last 12 months. * Participants who have taken 1 or more doses of zuranolone at the time of study screening. * Current or history of bipolar disorder. * Failure to complete baseline (Day 0) surveys. * Declined to consent. * Pregnancy that ended more than 12 months ago. Note: Other protocol-defined Inclusion/Exclusion criteria may apply.
Where it's running
-
Biogen
Cambridge, Massachusetts, United States Recruiting
Study contacts
- Study coordinator: US Biogen Clinical Trial Center
- Email: clinicaltrials@biogen.com
- Phone: 866-633-4636
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Smartphone-supported single-session psychotherapy for postpartum depression
A single online therapy session plus four weeks of app-based support is being tested to see if it reduces depressive symptoms in postpartum women compared with a waitlist.
-
Midwife-Led Digital Follow-Up After Cesarean Delivery
This trial tests whether a midwife-led, four-week digital follow-up after cesarean delivery improves mood, social support, and breastfeeding confidence compared with standard postpartum care.
-
Non-invasive zinc protoporphyrin screening for iron deficiency in pregnancy
This project tests a handheld device that measures zinc protoporphyrin through the lower lip to detect iron deficiency in pregnant and recently postpartum people.
-
Postpartum Depression: A Digital Decision Support Tool for Providers
A digital tool within the electronic health record helps clinicians identify patients at risk for postpartum depression and guide support on referrals and education.
-
Empowering mothers to prevent postpartum depression
This study is testing a new online program that helps first-time pregnant women use art to boost their mental health and reduce the risk of postpartum depression.
-
Understanding how ketamine works for pain and depression after cesarean delivery
This study is testing how ketamine can help manage pain and depression in new mothers after a cesarean delivery compared to healthy men and women who are not pregnant.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.